SCHEMBL4857014

SCHEMBL4857014

CSc1ccc(N=C(N)c2ccccc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.66
KMT2A Q03164 1/20 0.66
NOS1 P29475 8/20 0.61
NOS3 P29474 7/20 0.61
CYP2D6 P10635 1/20 0.56
HIF1A Q16665 1/20 0.56
QRFPR Q96P65 3/20 0.47
NPSR1 Q6W5P4 1/20 0.42
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41
AKR1C1 Q04828 1/20 0.41
ADRA2A P08913 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
HTR3E A5X5Y0 1/20 0.41
SLC22A2 O15244 1/20 0.41
SLC22A1 O15245 1/20 0.41
SLC22A3 O75751 1/20 0.41
HTR3B O95264 1/20 0.41
PLAU P00749 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4853071 0.84 CYP2D6 (0.64) MEN1KMT2ANOS1NOS3CYP2D6
SCHEMBL4852965 0.83 NOS1 (0.58) MEN1KMT2ANOS1NOS3CYP2D6
SCHEMBL4857038 0.83 NOS1 (0.58) MEN1KMT2ANOS1NOS3CYP2D6
SCHEMBL4854767 0.83 NOS1 (0.58) MEN1KMT2ANOS1NOS3CYP2D6
SCHEMBL4864124 0.83 NOS3 (0.58) MEN1KMT2ANOS1NOS3CYP2D6
SCHEMBL4856119 0.83 NOS3 (0.58) MEN1KMT2ANOS1NOS3CYP2D6
SCHEMBL24662980 0.80 KMT2A (1.00) MEN1KMT2ANOS1NOS3CYP2D6
SCHEMBL139363 0.80 KMT2A (1.00) MEN1KMT2ANOS1NOS3CYP2D6
SCHEMBL24136574 0.80 KMT2A (1.00) MEN1KMT2ANOS1NOS3CYP2D6
SCHEMBL4860016 0.80 NOS3 (0.54) MEN1KMT2ANOS1NOS3CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-20040259891-A1 Novel pyrimidon derivatives ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259891-A1 Novel pyrimidon derivatives TYMS, TPMT, TYMP MEN1 917/4885KMT2A 4298/4885NOS1 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.